Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec + Pembrolizumab in Recurrent/Metastatic SCCHN
NCT02626000Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2016
- Primary completion
- Nov 2017
- Modality
- Oncolytic Viruses
- Countries
- 11
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Amgen. Primary endpoint: Dose Limiting Toxicity at 6 weeks. Started Apr 2016; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02626000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626000.